Noostan (Piracetam)

Piracetam’s mechanism is not fully defined, but it is believed to modify neuronal membrane fluidity, influence AMPA and NMDA receptor activity, improve cerebral blood flow, and enhance synaptic plasticity. These actions may facilitate neurotransmission and neuroprotective processes that underlie its cognitive‑enhancing effects.

The appropriate dose of Noostan is determined by the prescribing clinician based on the patient’s age, clinical condition, and response to therapy. Dosage regimens can differ widely, and the prescriber will tailor the amount and frequency to achieve the desired therapeutic outcome while monitoring safety.

Safety data for piracetam during pregnancy and lactation are limited. Because potential risks cannot be excluded, it is generally advised to avoid use unless the potential benefit outweighs the possible harm, and only under direct medical supervision.

To request Noostan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with other racetams such as aniracetam or oxiracetam, piracetam has a longer safety record and is widely studied, but it may be less potent in some cognitive domains. Unlike stimulant‑type nootropics, piracetam does not act on dopamine pathways, offering a different side‑effect profile that may be preferable for certain patients.

Noostan should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture, heat and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Noostan is taken orally, typically as a tablet or capsule, and should be swallowed with water. The exact form and dosing schedule are prescribed by the treating physician, who will advise whether the medication should be taken with or without food based on individual tolerance.

Although uncommon, serious adverse reactions to piracetam can include severe allergic skin reactions such as rash or angio‑edema, and hematologic effects like thrombocytopenia. Patients should seek immediate medical attention if they develop unexplained bruising, bleeding, skin swelling, or signs of an allergic response while using Noostan.

Noostan is contraindicated in individuals with known hypersensitivity to piracetam or any excipients in the formulation. Caution is also advised for patients with severe renal or hepatic impairment, uncontrolled epilepsy, or those taking medications that may interact significantly, such as anticoagulants or certain anticonvulsants. The prescribing clinician will assess suitability before initiating therapy.